Masayuki Nakagawa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5732837/publications.pdf

Version: 2024-02-01

57 papers	2,441 citations	186265 28 h-index	197818 49 g-index
59	59	59	3793
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	The MicroRNA Expression Signature of Bladder Cancer by Deep Sequencing: The Functional Significance of the miR-195/497 Cluster. PLoS ONE, 2014, 9, e84311.	2.5	142
2	Elevated expression of vacuolar proton pump genes and cellular ph in cisplatin resistance. International Journal of Cancer, 2001, 93, 869-874.	5.1	128
3	Tumorâ€suppressive <i>micro<scp>RNA</scp>â€223</i> inhibits cancer cell migration and invasion by targeting <i><scp>ITGA</scp>3/<scp>ITGB</scp>1</i> signaling in prostate cancer. Cancer Science, 2016, 107, 84-94.	3.9	122
4	Dual tumorâ€suppressors <i>miRâ€139â€5p</i> and <i>miRâ€139â€3p</i> targeting <i>matrix metalloprotease in bladder cancer. Cancer Science, 2016, 107, 1233-1242.</i>	1 <u>1,</u> 5/i>	115
5	The i>microRNA-23b/27b/24-1 / i>cluster is a disease progression marker and tumor suppressor in prostate cancer. Oncotarget, 2014, 5, 7748-7759.	1.8	115
6	The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer. Journal of Human Genetics, 2014, 59, 78-87.	2.3	112
7	MicroRNA expression signature of castration-resistant prostate cancer: the microRNA-221/222 cluster functions as a tumour suppressor and disease progression marker. British Journal of Cancer, 2015, 113, 1055-1065.	6.4	107
8	Tumor-suppressive microRNA-29s inhibit cancer cell migration and invasion via targeting LAMC1 in prostate cancer. International Journal of Oncology, 2014, 45, 401-410.	3.3	93
9	Regulation of <i>UHRF1</i> by dual-strand tumor-suppressor <i>microRNA-145</i> (i>miR-145-5pand <i>miR-145-3p</i>): inhibition of bladder cancer cell aggressiveness. Oncotarget, 2016, 7, 28460-28487.	1.8	93
10	Dual regulation of receptor tyrosine kinase genes EGFR and c-Met by the tumor-suppressive microRNA-23b/27b cluster in bladder cancer. International Journal of Oncology, 2015, 46, 487-496.	3.3	82
11	Tumourâ€suppressive <i>microRNAâ€224</i> inhibits cancer cell migration and invasion via targeting oncogenic <i>TPD52</i> in prostate cancer. FEBS Letters, 2014, 588, 1973-1982.	2.8	76
12	The role of microRNAs in bladder cancer. Investigative and Clinical Urology, 2016, 57, S60.	2.0	75
13	Tumourâ€suppressive <i>microRNAâ€29s</i> directly regulate <i>LOXL2</i> expression and inhibit cancer cell migration and invasion in renal cell carcinoma. FEBS Letters, 2015, 589, 2136-2145.	2.8	66
14	Clinical Practice Guidelines for Bladder Cancer 2019 update by the Japanese Urological Association: Summary of the revision. International Journal of Urology, 2020, 27, 702-709.	1.0	65
15	MicroRNA-26a/b directly regulate La-related protein 1 and inhibit cancer cell invasion in prostate cancer. International Journal of Oncology, 2015, 47, 710-718.	3.3	62
16	Downregulation of the microRNA-1/133a cluster enhances cancer cell migration and invasion in lung-squamous cell carcinoma via regulation of Coronin1C. Journal of Human Genetics, 2015, 60, 53-61.	2.3	61
17	PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2α-Targeting Therapy for Renal Cell Carcinoma. Cancer Research, 2017, 77, 6321-6329.	0.9	60
18	Tumor-suppressive microRNAs (miR-26a/b, miR-29a/b/c and miR-218) concertedly suppressed metastasis-promoting LOXL2 in head and neck squamous cell carcinoma. Journal of Human Genetics, 2016, 61, 109-118.	2.3	59

#	Article	IF	CITATIONS
19	microRNA-210-3p depletion by CRISPR/Cas9 promoted tumorigenesis through revival of TWIST1 in renal cell carcinoma. Oncotarget, 2017, 8, 20881-20894.	1.8	57
20	Tumor-suppressive microRNA-29 family inhibits cancer cell migration and invasion directly targeting LOXL2 in lung squamous cell carcinoma. International Journal of Oncology, 2016, 48, 450-460.	3. 3	55
21	Expression of the Tumor SuppressivemiRNA-23b/27bCluster is a Good Prognostic Marker in Clear Cell Renal Cell Carcinoma. Journal of Urology, 2014, 192, 1822-1830.	0.4	52
22	Tumour-suppressivemicroRNA-24-1inhibits cancer cell proliferation through targetingFOXM1in bladder cancer. FEBS Letters, 2014, 588, 3170-3179.	2.8	52
23	Regulation of ITGA3 by the dual-stranded microRNA-199 family as a potential prognostic marker in bladder cancer. British Journal of Cancer, 2017, 116, 1077-1087.	6.4	48
24	Tumor-suppressive microRNA-206 as a dual inhibitor of MET and EGFR oncogenic signaling in lung squamous cell carcinoma. International Journal of Oncology, 2015, 46, 1039-1050.	3.3	40
25	Genome-wide association study identified SNP on 15q24 associated with bladder cancer risk in Japanese population. Human Molecular Genetics, 2015, 24, 1177-1184.	2.9	38
26	Potential new therapy of Rapalinkâ€1, a new generation mammalian target of rapamycin inhibitor, against sunitinibâ€resistant renal cell carcinoma. Cancer Science, 2020, 111, 1607-1618.	3.9	38
27	<i>MicroRNAâ€205</i> inhibits cancer cell migration and invasion via modulation of <i>centromere protein F</i> regulating pathways in prostate cancer. International Journal of Urology, 2015, 22, 867-877.	1.0	29
28	Occurrence of infection following prostate biopsy procedures in Japan. Journal of Infection and Chemotherapy, 2014, 20, 232-237.	1.7	28
29	Bromodomain protein BRD4 inhibitor JQ1 regulates potential prognostic molecules in advanced renal cell carcinoma. Oncotarget, 2018, 9, 23003-23017.	1.8	28
30	Endoscopic treatment of a long fibroepithelial ureteral polyp. International Journal of Urology, 2001, 8, 467-469.	1.0	27
31	Clinical Practice Guidelines for Bladder Cancer 2019 edition by the Japanese Urological Association: Revision working position paper. International Journal of Urology, 2020, 27, 362-368.	1.0	25
32	The tumor-suppressive microRNA-1/133a cluster targets PDE7A and inhibits cancer cell migration and invasion in endometrial cancer. International Journal of Oncology, 2015, 47, 325-334.	3.3	24
33	Mucinous adenocarcinoma emerging in sigmoid colon neovagina 40Âyears after its creation: a case report. World Journal of Surgical Oncology, 2015, 13, 213.	1.9	24
34	Potential tumorâ€'suppressive role of microRNAâ€'99aâ€'3p in sunitinibâ€'resistant renal cell carcinoma cells through the regulation of RRM2. International Journal of Oncology, 2019, 54, 1759-1770.	3.3	24
35	HRAS as a potential therapeutic target of salirasib RAS inhibitor in bladder cancer. International Journal of Oncology, 2018, 53, 725-736.	3.3	22
36	Targeting NPL4 via drug repositioning using disulfiram for the treatment of clear cell renal cell carcinoma. PLoS ONE, 2020, 15, e0236119.	2.5	20

#	Article	IF	Citations
37	Oncogenic effects of RAB27B through exosome independent function in renal cell carcinoma including sunitinib-resistant. PLoS ONE, 2020, 15, e0232545.	2.5	19
38	EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer. BMC Cancer, 2021, 21, 48.	2.6	19
39	Downregulation of microRNA-1274a induces cell apoptosis through regulation of BMPR1B in clear cell renal cell carcinoma. Oncology Reports, 2017, 39, 173-181.	2.6	18
40	Characterization of <i>PHGDH</i> expression in bladder cancer: potential targeting therapy with gemcitabine/cisplatin and the contribution of promoter DNA hypomethylation. Molecular Oncology, 2020, 14, 2190-2202.	4.6	17
41	Tumorâ€'suppressive microRNAâ€'223 targets WDR62 directly in bladder cancer. International Journal of Oncology, 2019, 54, 2222-2236.	3.3	16
42	Acute Kidney Injury and Rhabdomyolysis After Protobothrops flavoviridis Bite: A Retrospective Survey of 86 Patients in a Tertiary Care Center. American Journal of Tropical Medicine and Hygiene, 2016, 94, 474-479.	1.4	14
43	A new risk stratification model for intravesical recurrence, disease progression, and cancer-specific death in patients with non-muscle invasive bladder cancer: the J-NICE risk tables. International Journal of Clinical Oncology, 2020, 25, 1364-1376.	2.2	14
44	Expression of ABCB6 is related to resistance to 5-FU, SN-38 and vincristine. Anticancer Research, 2014, 34, 4767-73.	1.1	14
45	Immunoadsorption plasmapheresis treatment for the recurrent exacerbation of neuromyelitis optica spectrum disorder with a fluctuating anti-aquaporin-4 antibody level. Journal of Artificial Organs, 2018, 21, 378-382.	0.9	8
46	The long-term prognosis of nephropathy in operated reflux. Journal of Pediatric Urology, 2019, 15, 605.e1-605.e8.	1.1	6
47	Anatomical Variations of the Left Renal Vein During Laparoscopic Donor Nephrectomy. Transplantation Proceedings, 2019, 51, 1311-1313.	0.6	6
48	Oncological outcome of neoadjuvant low-dose estramustine plus LHRH agonist/antagonist followed by extended radical prostatectomy for Japanese patients with high-risk localized prostate cancer: a prospective single-arm study. Japanese Journal of Clinical Oncology, 2020, 50, 66-72.	1.3	5
49	Is It Safe to Use the Same Scissors After Accidental Tumor Incision During Partial Nephrectomy? Results of <i>In Vitro</i> and <i>In Vivo</i> Experiments. Journal of Endourology, 2017, 31, 391-395.	2.1	4
50	Targeting of the glutamine transporter SLC1A5 induces cellular senescence in clear cell renal cell carcinoma. Biochemical and Biophysical Research Communications, 2022, 611, 99-106.	2.1	4
51	Long-term desensitization for ABO-incompatible living related kidney transplantation recipients with high refractory and rebound anti-blood type antibody: case report. BMC Nephrology, 2018, 19, 254.	1.8	3
52	Oral Propranolol in a Child With Infantile Hemangioma of the Urethra. Urology, 2018, 122, 165-168.	1.0	3
53	Surveillance of urachal abscess in the Kyushu–Okinawa area of Japan. International Journal of Urology, 2021, 28, 1008-1011.	1.0	2
54	Successful Kidney Transplantation Alone With Severe Left Ventricular Systolic Dysfunction of Ejection Fraction 14%: A Case Report. Transplantation Proceedings, 2020, 52, 1919-1923.	0.6	1

#	Article	IF	CITATIONS
55	Kidney transplantation with concomitant simple nephrectomy by thoracoabdominal approach for patients with huge autosomal dominant polycystic kidney disease (ADPKD): A case report. Urology Case Reports, 2019, 26, 100973.	0.3	0
56	Significance of preoperative screening of deep vein thrombosis and its indications for patients undergoing urological surgery. Investigative and Clinical Urology, 2021, 62, 166.	2.0	0
57	Clinicopathological features of renal cell carcinoma complicated by ACDK in chronic hemodialysis patients Nihon Toseki Igakkai Zasshi, 2002, 35, 1495-1501.	0.1	0